EuroQol (EQ-5D-5L) Validity in Assessing the Quality of Life in Adults With Asthma: Cross-Sectional Study

Gimena Hernandez, Olatz Garin, Alexandra L Dima, Angels Pont, Marc Martí Pastor, Jordi Alonso, Eric Van Ganse, Laurent Laforest, Marijn de Bruin, Karina Mayoral, Vicky Serra-Sutton, Montse Ferrer, ASTRO-LAB Group, Sandrine Herbage, Manon Belhassen, Marine Ginoux, Stéphane Schück, Nathalie Texier, Sandy Leproust, Hélène Le Cloarec, Richard Hubbard, Alison Bourke, Thompson Mary, Delphine Vial, David Ansell, Olaiz Javier, Ana Valcarcel Orti, Gimena Hernandez, Olatz Garin, Alexandra L Dima, Angels Pont, Marc Martí Pastor, Jordi Alonso, Eric Van Ganse, Laurent Laforest, Marijn de Bruin, Karina Mayoral, Vicky Serra-Sutton, Montse Ferrer, ASTRO-LAB Group, Sandrine Herbage, Manon Belhassen, Marine Ginoux, Stéphane Schück, Nathalie Texier, Sandy Leproust, Hélène Le Cloarec, Richard Hubbard, Alison Bourke, Thompson Mary, Delphine Vial, David Ansell, Olaiz Javier, Ana Valcarcel Orti

Abstract

Background: The EuroQol-5 Dimension (EQ-5D), developed in 1990, is a most widely used generic tool to measure the health-related quality of life (HRQoL) and considered suitable for patients with asthma. In 2009, the EuroQol Group developed a new EQ-5D version to overcome limitations related to its consistently reported high ceiling effect. To enhance the sensitivity for assessing the HRQoL in further patient populations, the number of responses of EQ-5D was increased from 3 to 5 levels (EQ-5D-5L). Moreover, the availability of well-defined requirements for its Web-based administration allows EQ-5D-5L use to monitor the HRQoL in electronic health (eHealth) programs. No study has evaluated the metric properties of the new EQ-5D-5L in patients with asthma yet.

Objective: This study aims to examine the distribution, construct validity, and reliability of the new EQ-5D-5L questionnaire administered online to adults with asthma.

Methods: We evaluated patients with asthma (age: 18-40 years) from a primary care setting in France and England, who self-completed the EQ-5D-5L questionnaire online. The inclusion criteria were persistent asthma defined as >6 months of prescribed inhaled corticosteroids and long-acting beta-agonists or inhaled corticosteroids alone during the 12 months prior to inclusion. The EQ-5D index was obtained by applying the English preference value set for the new EQ-5D-5L and the French 3L-5L crosswalk value set. Both value sets produced single preference-based indices ranging from 1 (best health state) to negative values (health states valued as worse than death), where 0=death, allowing the calculation of quality-adjusted life years. Responses to dimensions and index distribution, including ceiling and floor effects, were examined. The construct validity was assessed by comparing the means of known groups by analyses of variance and calculation of effect sizes.

Results: Of 312 patients answering the baseline Web-based survey, 290 completed the EQ-5D-5L (93%). The floor effect was null, and the ceiling effect was 26.5% (74/279). The mean EQ-5D-5L index was 0.88 (SD 0.14) with the English value set and 0.83 (SD 0.19) with the French 3L-5L crosswalk value set. In both indices, large effect sizes were observed for known groups defined by the Asthma Control Questionnaire (1.06 and 1.04, P<.001). Differences between extreme groups defined by chronic conditions (P=.002 and P=.003 for the English value set and French 3L-5L crosswalk value set, respectively), short-acting beta-agonists (SABAs) canisters in the last 12 months (P=.02 and P=.03), or SABA use during the previous 4 weeks (P=.03 and P=.01) were of moderate magnitude with effect sizes around 0.5.

Conclusions: The new EQ-5D-5L questionnaire has an acceptable ceiling effect, a good construct validity based on the discriminant ability for distinguishing among health-related known groups, and high reliability, supporting its adequacy for assessing the HRQoL in patients with asthma. EQ-5D-5L completion by most Web-based respondents supports the feasibility of this administration form.

Keywords: EQ-5D-5L; EuroQol; Web-based survey; asthma; health-related quality of life; patient-reported outcome measures; validity.

Conflict of interest statement

Conflicts of Interest: None declared.

©Gimena Hernandez, Olatz Garin, Alexandra L Dima, Angels Pont, Marc Martí Pastor, Jordi Alonso, Eric Van Ganse, Laurent Laforest, Marijn de Bruin, Karina Mayoral, Vicky Serra-Sutton, Montse Ferrer, ASTRO-LAB Group. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 23.01.2019.

Figures

Figure 1
Figure 1
The percentage of patients’ responses to each dimension.

References

    1. Carranza RJR, Edwards L, Lincourt W, Dorinsky P, ZuWallack RL. The relationship between health-related quality of life, lung function and daily symptoms in patients with persistent asthma. Respir Med. 2004 Dec;98(12):1157–65.
    1. McKenna SP. Measuring patient-reported outcomes: moving beyond misplaced common sense to hard science. BMC Med. 2011 Jul 14;9:86. doi: 10.1186/1741-7015-9-86.
    1. Global Initiative for Asthma. 2018. [2018-09-26]. Global Strategy for Asthma Management and Prevention .
    1. Stucky BD, Sherbourne CD, Edelen MO, Eberhart NK. Understanding asthma-specific quality of life: moving beyond asthma symptoms and severity. Eur Respir J. 2015 Sep;46(3):680–7. doi: 10.1183/09031936.00225014.
    1. Chen H, Gould MK, Blanc PD, Miller DP, Kamath TV, Lee JH, Sullivan SD, TENOR Study Group Asthma control, severity, and quality of life: quantifying the effect of uncontrolled disease. J Allergy Clin Immunol. 2007 Aug;120(2):396–402. doi: 10.1016/j.jaci.2007.04.040.
    1. Schatz M, Mosen DM, Kosinski M, Vollmer WM, Magid DJ, O'Connor E, Zeiger RS. The relationship between asthma-specific quality of life and asthma control. J Asthma. 2007 Jun;44(5):391–5. doi: 10.1080/02770900701364296.
    1. Hunger M, Sabariego C, Stollenwerk B, Cieza A, Leidl R. Validity, reliability and responsiveness of the EQ-5D in German stroke patients undergoing rehabilitation. Qual Life Res. 2012 Sep;21(7):1205–16. doi: 10.1007/s11136-011-0024-3.
    1. König H, Born A, Günther O, Matschinger H, Heinrich S, Riedel-Heller SG, Angermeyer MC, Roick C. Validity and responsiveness of the EQ-5D in assessing and valuing health status in patients with anxiety disorders. Health Qual Life Outcomes. 2010 May 05;8:47. doi: 10.1186/1477-7525-8-47.
    1. Hung M, Lu W, Chen S, Hou W, Hsieh C, Wang J. Validation of the EQ-5D in Patients with Traumatic Limb Injury. J Occup Rehabil. 2015 Jun;25(2):387–93. doi: 10.1007/s10926-014-9547-0.
    1. EQ-5D. [2018-09-26]. EQ-5D User Guides .
    1. Gibbons E, Fitzpatrick R. Patient Reported Outcome Measurement Group, Oxford. The University of Oxford: Oxford, UK; 2009. [2018-09-26]. A structured review of patient-reported outcome measures (PROMs) for asthma .
    1. Räsänen P, Roine E, Sintonen H, Semberg-Konttinen V, Ryynänen O, Roine R. Use of quality-adjusted life years for the estimation of effectiveness of health care: A systematic literature review. Int J Technol Assess Health Care. 2006;22(2):235–41. doi: 10.1017/S0266462306051051.
    1. Richardson J, McKie J, Bariola E. Multi attribute utility instruments and their use. In: Culyer AJ, editor. Encyclopedia of health economics. San Diego: Elsevier Science; 2014. pp. 341–357.
    1. Fauteux V, Poder T. État des lieux sur les méthodes d’élicitation du QALY Overview of QALY elicitation methods. Int J Health Pref Research. 2017;1:001–14. doi: 10.21965/IJHPR.2017.001.
    1. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T, Mishima M. A comparison of the responsiveness of different generic health status measures in patients with asthma. Qual Life Res. 2003 Aug;12(5):555–63.
    1. Garratt AM, Hutchinson A, Russell I. Patient-assessed measures of health outcome in asthma: a comparison of four approaches. Respir Med. 2000 Jun;94(6):597–606. doi: 10.1053/rmed.2000.0787.
    1. McTaggart-Cowan HM, Marra CA, Yang Y, Brazier JE, Kopec JA, FitzGerald JM, Anis AH, Lynd LD. The validity of generic and condition-specific preference-based instruments: the ability to discriminate asthma control status. Qual Life Res. 2008 Apr;17(3):453–62. doi: 10.1007/s11136-008-9309-6.
    1. Brazier J, Roberts J, Tsuchiya A, Busschbach J. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ. 2004 Sep;13(9):873–84. doi: 10.1002/hec.866.
    1. Janssen MF, Lubetkin EI, Sekhobo JP, Pickard AS. The use of the EQ-5D preference-based health status measure in adults with Type 2 diabetes mellitus. Diabet Med. 2011 Apr;28(4):395–413. doi: 10.1111/j.1464-5491.2010.03136.x.
    1. van Stel HF, Buskens E. Comparison of the SF-6D and the EQ-5D in patients with coronary heart disease. Health Qual Life Outcomes. 2006 Mar 25;4:20. doi: 10.1186/1477-7525-4-20.
    1. Feeny D, Furlong W, Torrance GW, Goldsmith CH, Zhu Z, DePauw S, Denton M, Boyle M. Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Med Care. 2002 Feb;40(2):113–28.
    1. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002 Mar;21(2):271–92.
    1. Oppe M, Devlin NJ, van Hout B, Krabbe PFM, De Leon MC. A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol. Value Health. 2014 Jun;17(4):445–53. doi: 10.1016/j.jval.2014.04.002.
    1. Pickard AS, De Leon MC, Kohlmann T, Cella D, Rosenbloom S. Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients. Med Care. 2007 Mar;45(3):259–63. doi: 10.1097/01.mlr.0000254515.63841.81.
    1. Kim SH, Kim HJ, Lee S, Jo M. Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L in cancer patients in Korea. Qual Life Res. 2012 Aug;21(6):1065–73. doi: 10.1007/s11136-011-0018-1.
    1. Jia YX, Cui FQ, Li L, Zhang DL, Zhang GM, Wang FZ, Gong XH, Zheng H, Wu ZH, Miao N, Sun XJ, Zhang L, Lv JJ, Yang F. Comparison between the EQ-5D-5L and the EQ-5D-3L in patients with hepatitis B. Qual Life Res. 2014 Oct;23(8):2355–63. doi: 10.1007/s11136-014-0670-3.
    1. Van Ganse E, Texier N, Dima AL, Laforest L, Ferrer M, Hernandez G, Schuck S, Herbage S, Vial D, de Bruin M, ASTRO-LAB group Assessment of the safety of long-acting β2-agonists in routine asthma care: the ASTRO-LAB protocol. NPJ Prim Care Respir Med. 2015 Jun 18;25:15040. doi: 10.1038/npjpcrm.2015.40.
    1. Schatz M, Zeiger RS, Yang ST, Chen W, Crawford WW, Sajjan SG, Allen-Ramey F. Relationship of asthma control to asthma exacerbations using surrogate markers within a managed care database. Am J Manag Care. 2010 May;16(5):327–33.
    1. van Hout B, Janssen MF, Feng Y, Kohlmann T, Busschbach J, Golicki D, Lloyd A, Scalone L, Kind P, Pickard AS. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708–15. doi: 10.1016/j.jval.2012.02.008.
    1. Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B. Valuing health-related quality of life: An EQ-5D-5L value set for England. Health Econ. 2018 Jan;27(1):7–22. doi: 10.1002/hec.3564.
    1. McClure NS, Sayah FA, Xie F, Luo N, Johnson JA. Instrument-Defined Estimates of the Minimally Important Difference for EQ-5D-5L Index Scores. Value Health. 2017 Apr;20(4):644–650. doi: 10.1016/j.jval.2016.11.015.
    1. Reddel HK, Taylor DR, Bateman ED, Boulet L, Boushey HA, Busse WW, Casale TB, Chanez P, Enright PL, Gibson PG, de Jongste JC, Kerstjens HAM, Lazarus SC, Levy ML, O'Byrne PM, Partridge MR, Pavord ID, Sears MR, Sterk PJ, Stoloff SW, Sullivan SD, Szefler SJ, Thomas MD, Wenzel SE, American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009 Jul 1;180(1):59–99. doi: 10.1164/rccm.200801-060ST.
    1. Taylor DR, Bateman ED, Boulet L, Boushey HA, Busse WW, Casale TB, Chanez P, Enright PL, Gibson PG, de Jongste JC, Kerstjens HAM, Lazarus SC, Levy ML, O'Byrne PM, Partridge MR, Pavord ID, Sears MR, Sterk PJ, Stoloff SW, Szefler SJ, Sullivan SD, Thomas MD, Wenzel SE, Reddel HK. A new perspective on concepts of asthma severity and control. Eur Respir J. 2008 Sep;32(3):545–54. doi: 10.1183/09031936.00155307.
    1. Juniper EF, Svensson K, Mörk A, Ståhl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med. 2005 May;99(5):553–8. doi: 10.1016/j.rmed.2004.10.008.
    1. Juniper EF, Bousquet J, Abetz L, Bateman ED. Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire. Respir Med. 2006 Apr;100(4):616–21. doi: 10.1016/j.rmed.2005.08.012.
    1. Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, Bouter LM, de Vet HC. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol. 2007 Jan;60(1):34–42. doi: 10.1016/j.jclinepi.2006.03.012.
    1. Aaronson N, Alonso J, Burnam A, Lohr KN, Patrick DL, Perrin E, Stein RE. Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res. 2002 May;11(3):193–205.
    1. Chen W, Lynd LD, FitzGerald JM, Marra CA, Rousseau R, Sadatsafavi M. The added effect of comorbidity on health-related quality of life in patients with asthma. Qual Life Res. 2015 Oct;24(10):2507–17. doi: 10.1007/s11136-015-0995-6.
    1. Moy ML, Fuhlbrigge AL, Blumenschein K, Chapman RH, Zillich AJ, Kuntz KM, Paltiel AD, Kitch BT, Weiss ST, Neumann PJ. Association between preference-based health-related quality of life and asthma severity. Ann Allergy Asthma Immunol. 2004 Mar;92(3):329–34. doi: 10.1016/S1081-1206(10)61570-0.
    1. Cohen J. Statistical Power Analysis for the Behavioral Sciences. New York: Taylor & Francis, Inc; 1988.
    1. Kongsved SM, Basnov M, Holm-Christensen K, Hjollund NH. Response rate and completeness of questionnaires: a randomized study of Internet versus paper-and-pencil versions. J Med Internet Res. 2007;9(3):e25. doi: 10.2196/jmir.9.3.e25.
    1. Ritter P, Lorig K, Laurent D, Matthews K. Internet versus mailed questionnaires: a randomized comparison. J Med Internet Res. 2004 Sep 15;6(3):e29. doi: 10.2196/jmir.6.3.e29.
    1. Scott A, Jeon S, Joyce CM, Humphreys JS, Kalb G, Witt J, Leahy A. A randomised trial and economic evaluation of the effect of response mode on response rate, response bias, and item non-response in a survey of doctors. BMC Med Res Methodol. 2011;11:126. doi: 10.1186/1471-2288-11-126.
    1. Fouladi RT, McCarthy CJ, Moller NP. Paper-and-pencil or online? Evaluating mode effects on measures of emotional functioning and attachment. Assessment. 2002 Jun;9(2):204–15. doi: 10.1177/10791102009002011.
    1. Ekman A, Dickman PW, Klint A, Weiderpass E, Litton J. Feasibility of using web-based questionnaires in large population-based epidemiological studies. Eur J Epidemiol. 2006;21(2):103–11. doi: 10.1007/s10654-005-6030-4.
    1. Hohwü L, Lyshol H, Gissler M, Jonsson SH, Petzold M, Obel C. Web-based versus traditional paper questionnaires: a mixed-mode survey with a Nordic perspective. J Med Internet Res. 2013;15(8):e173. doi: 10.2196/jmir.2595.
    1. Augustovski F, Rey-Ares L, Irazola V, Garay OU, Gianneo O, Fernández G, Morales M, Gibbons L, Ramos-Goñi JM. An EQ-5D-5L value set based on Uruguayan population preferences. Qual Life Res. 2016 Feb;25(2):323–33. doi: 10.1007/s11136-015-1086-4.
    1. Xie F, Pullenayegum E, Gaebel K, Bansback N, Bryan S, Ohinmaa A, Poissant L, Johnson JA, Canadian EVSG. A Time Trade-off-derived Value Set of the EQ-5D-5L for Canada. Med Care. 2016 Jan;54(1):98–105. doi: 10.1097/MLR.0000000000000447.
    1. Kim S, Ahn J, Ock M, Shin S, Park J, Luo N, Jo M. The EQ-5D-5L valuation study in Korea. Qual Life Res. 2016 Dec;25(7):1845–52. doi: 10.1007/s11136-015-1205-2.
    1. Xie F, Pullenayegum E, Gaebel K, Oppe M, Krabbe PFM. Eliciting preferences to the EQ-5D-5L health states: discrete choice experiment or multiprofile case of best–worst scaling? Eur J Health Econ. 2013 Apr 4;15(3):281–288. doi: 10.1007/s10198-013-0474-3.
    1. Versteegh MM, Vermeulen KM, Evers SMAA, de Wit GA, Prenger R, Stolk EA. Dutch Tariff for the Five-Level Version of EQ-5D. Value Health. 2016 Dec;19(4):343–52. doi: 10.1016/j.jval.2016.01.003.
    1. Chevalier J, de Pouvourville G. Valuing EQ-5D using time trade-off in France. Eur J Health Econ. 2013 Feb;14(1):57–66. doi: 10.1007/s10198-011-0351-x.
    1. King MT, Kenny PM, Marks GB. Measures of asthma control and quality of life: longitudinal data provide practical insights into their relative usefulness in different research contexts. Qual Life Res. 2009 Apr;18(3):301–12. doi: 10.1007/s11136-009-9448-4.
    1. Worth A, Hammersley V, Knibb R, Flokstra-de-Blok B, DunnGalvin A, Walker S, Dubois AEJ, Sheikh A. Patient-reported outcome measures for asthma: a systematic review. NPJ Prim Care Respir Med. 2014 Jun 26;24:14020. doi: 10.1038/npjpcrm.2014.20.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel